Sanofi Takes Sun To Court Over Generic Eloxatin

Law360, San Diego (June 21, 2011, 4:25 PM EDT) -- Sanofi-Aventis SA filed a suit Friday in New Jersey seeking to block Sun Pharmaceutical Industries Ltd. from launching a generic version of the French drugmaker’s colorectal cancer treatment Eloxatin before August 2012 as provided under a license agreement between the parties.

Sanofi, along with its U.S. unit and Swiss pharmaceutical arm Debiopharm SA, brought the infringement suit in response to India-based Sun’s filing of an abbreviated new drug application to make and sell injectable oxaliplatin formulations, and including certifications that U.S. Patent Numbers 5,338,874 and 5,716,988...
To view the full article, register now.